Is Immutep Limited (IMMP) a Buy, Sell, or Hold?
Immutep Limited
NASDAQ:IMMP
$0.4328 USD
-$0.02 (-3.93%)
- Volume
- 0
- Average Volume
- 13.76M
- Market Capitalization
- $63.78M
- P/E Ratio
- -0.96
- Dividend Yield
- 0.00%
- Price Target
- $4.25
- Year High
- $3.53
- Year Low
- $0.29
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $2.97
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Marc Voigt |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | IMMP |
| CUSIP | 45257L108 |
| CIK | 0001506184 |
| Web | https://www.immutep.com |
| Phone | 61 2 8315 7003 |
| Currency | USD |
| Employees | 53 |
| Country | AU |
Liquidity
| Debt-to-Equity Ratio | 0.02 |
| Payout Ratio | 0.00 |
| Current Ratio | 2.97 |
| Quick Ratio | 2.97 |
| Cash Ratio | 1.55 |
Sales & Book Value
| Annual Sales | $5.04M |
| Price / Sales | 13.56 |
| Cash Flow | -0.04 |
| Price / Cash Flow | -1.30 |
| Price / Book | 0.82 |
Price Target and Rating
| Average Stock Price Forecast | $4.25 |
| High Stock Price Forecast | $5.00 |
| Low Stock Price Forecast | $3.50 |
| Forecast Upside/Downside | -89.82% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 4 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-0.42 |
| Trailing P/E Ratio | -0.96 |
| PEG Ratio | 0.02 |
| P/E Growth | 0.02 |
| Net Income | $-61.43M |
| Net Margin | -1404.13% |
| Pretax Margin | -1404.13% |
| Return on Equity | -69.20% |
| Return on Assets | -57.01% |
Financials Score
| AltmanZ Score | -5.60 |
| Piotroski Score | 3.00 |
| Working Capital | 92.78M |
| Total Assets | 147.2M |
| Ebit | -134.47M |
| Market Cap | 95.99M |
| Total Liabilities | 48.3M |
Poll Results
About Immutep Limited (NASDAQ:IMMP) Stock
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); INSIGHT-005 which is in phase I for metastatic urothelial carcinoma; TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phas ... e II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma. It also develops INSIGHT-003, which is in phase I trial 1L non squamous NSCL; INSIGHT-005 that is in phase I to treat metastatic urothelial cancer; IMP761, which is in phase I Trial to treat autoimmune disease; IMP731 for oncology and autoimmune diseases; and LAG525. Immutep has collaboration with Merck & Co., Inc., EOC Pharma, Novartis, and Laboratory Corporation of America Holdings. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is based in Sydney, Australia.
2026-07-13 08:00:00
SYDNEY, AUSTRALIA, July 13, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel immunotherapies, today announced a significant positive update of the investigator-initiated INSIGHT-003 Phase I trial evaluating eftilagimod alfa (efti) in combination with MSD's (Merck & Co. Inc., Rahway, NJ, USA) anti-PD-1 therapy KEYTRUDA® (pembrolizumab) and chemotherapy as 1st line therapy for advanced/metastatic non-small cell lung cancer (1L NSCLC) in 51 evaluable non-squamous patients.
2026-07-06 14:31:00
LOS ANGELES, July 6, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Immutep Limited ("Immutep" or "the Company") (NASDAQ: IMMP) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of IMMP during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments.
2026-07-06 09:00:00
[url="]The Schall Law Firm[/url], a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Immutep Limited (âImmute
2026-07-06 08:28:00
LOS ANGELES--(BUSINESS WIRE)---- $IMMP--IMMP Investors Have Opportunity to Lead Immutep Limited Securities Fraud Lawsuit with the Schall Law Firm.
2026-07-02 12:00:00
New York, New York--(Newsfile Corp. - July 2, 2026) - Bronstein, Gewirtz and Grossman, LLC, a nationally recognized investor-rights law
2026-07-02 10:10:00
LOS ANGELES, July 02, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Immutep Limited (“Immutep” or “the Company”) (NASDAQ: IMMP) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between March 24, 2025 and March 12, 2026, inclusive (the “Class Period”), are encouraged to contact the firm before July 6, 2026.
2026-07-02 10:00:00
NEW YORK, July 2, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Immutep Limited ("Immutep" or the "Company") (NASDAQ: IMMP). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
2026-07-01 09:34:00
NEW YORK, July 01, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Immutep Limited (“Immutep” or the “Company”) (NASDAQ: IMMP) investors of the July 6, 2026 deadline involving a securities fraud class action lawsuit commenced against the Company. Should You Join The Immutep Class Action Lawsuit : Do you, or did you, own shares of Immutep Limited (NASDAQ: IMMP)?
Frequently Asked Questions
-
What is the current Immutep Limited (IMMP) stock price?
-
Immutep Limited(NASDAQ:IMMP) stock price is $0.4328 in the last trading session. During the trading session, IMMP stock reached the peak price of $3.53 while $0.29 was the lowest point it dropped to. The percentage change in IMMP stock occurred in the recent session was --3.93% while the dollar amount for the price change in IMMP stock was -$-0.02.
-
IMMP's industry and sector of operation?
-
The NASDAQ listed IMMP is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of IMMP?
-
Indira Naidu | Joint Company Secretary
Frederic Triebel | Chief Scientific Officer & Executive Director
Stephan Winckels | Chief Medical Officer
Christian Mueller | Chief Development Officer
Marc Voigt | Chief Executive Officer, MD, Chief Financial Officer, Chief Business Officer & Executive Director -
How many employees does IMMP have?
-
Number of IMMP employees currently stands at 53. IMMP operates from Australia Square, Sydney, NSW 2000, AU.
-
Link for IMMP official website?
-
Official Website of IMMP is: https://www.immutep.com
-
How do I contact IMMP?
-
IMMP could be contacted at phone #61 2 8315 7003 and can also be accessed through its website. IMMP operates from Australia Square, Sydney, NSW 2000, AU.
-
How many shares of IMMP are traded daily?
-
The average number of IMMP shares traded daily for last 3 months was 13.76M.
-
What is the market cap of IMMP currently?
-
The market value of IMMP currently stands at $63.78M with its latest stock price at $0.4328